These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 6447180)

  • 1. Quantitative determination of fibrin and fibrinogen in biological material.
    Haeberli A; Straub PW
    J Lab Clin Med; 1980 Aug; 96(2):258-66. PubMed ID: 6447180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The fibrin and plasma-protein content of human thrombi].
    Jakab T; Haeberli A; Straub PW
    Schweiz Med Wochenschr; 1979 Sep; 109(37):1389. PubMed ID: 482912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The monoclonal antibody that recognizes an epitope in the C-terminal region of the fibrinogen alpha-chain reacts with soluble fibrin and fibrin monomer generated by thrombin but not with those formed as plasmin degradation products.
    Suzuki A; Ebinuma H; Matsuo M; Miyazaki O; Yago H
    Thromb Res; 2007; 121(3):377-85. PubMed ID: 17561232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunohistochemical characterization of fibrin(ogen)-related antigens in human tissues using monoclonal antibodies.
    Bini A; Mesa-Tejada R; Fenoglio JJ; Kudryk B; Kaplan KL
    Lab Invest; 1989 Jun; 60(6):814-21. PubMed ID: 2659890
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fibrin detected in plasma of patients with disseminated intravascular coagulation by fibrin-specific antibodies consists primarily of high molecular weight factor XIIIa-crosslinked and plasmin-modified complexes partially containing fibrinopeptide A.
    Pfitzner SA; Dempfle CE; Matsuda M; Heene DL
    Thromb Haemost; 1997 Sep; 78(3):1069-78. PubMed ID: 9308756
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progressive exposure of E-neoantigen associated with degradation of crosslinked fibrin by plasmin in vitro.
    Stegnar M; Chen JP
    Thromb Haemost; 1984 Dec; 52(3):315-20. PubMed ID: 6241755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluorogenic fibrinogen and fibrin facilitate macromolecular assembly and dynamic assay of picomolar levels of plasminogen activators under well mixed conditions.
    Wu JH; Diamond SL
    Thromb Haemost; 1995 Aug; 74(2):711-7. PubMed ID: 8585011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevated plasma levels of crosslinked fibrinogen gamma-chain dimer indicate cancer-related fibrin deposition and fibrinolysis.
    Gerner C; Steinkellner W; Holzmann K; Gsur A; Grimm R; Ensinger C; Obrist P; Sauermann G
    Thromb Haemost; 2001 Mar; 85(3):494-501. PubMed ID: 11307821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A molecular model of plasmic degradation of crosslinked fibrin.
    Francis CW; Marder VJ
    Semin Thromb Hemost; 1982 Jan; 8(1):25-35. PubMed ID: 6460319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma and platelet fibrinogen differ in gamma chain content.
    Francis CW; Nachman RL; Marder VJ
    Thromb Haemost; 1984 Feb; 51(1):84-8. PubMed ID: 6719392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Degradation of cross-linked fibrin by matrix metalloproteinase 3 (stromelysin 1): hydrolysis of the gamma Gly 404-Ala 405 peptide bond.
    Bini A; Itoh Y; Kudryk BJ; Nagase H
    Biochemistry; 1996 Oct; 35(40):13056-63. PubMed ID: 8855941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fibrin degradation products. A review of structures found in vitro and in vivo.
    Gaffney PJ
    Ann N Y Acad Sci; 2001; 936():594-610. PubMed ID: 11460518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The receptor for the globular "heads" of C1q, gC1q-R, binds to fibrinogen/fibrin and impairs its polymerization.
    Lu PD; Galanakis DK; Ghebrehiwet B; Peerschke EI
    Clin Immunol; 1999 Mar; 90(3):360-7. PubMed ID: 10075865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Fibrinogen fragment D - inhibitor of fibrinolytic processes].
    Rozenfel'd MA; Fateeva LA; Gontar' ID
    Biokhimiia; 1983 Jul; 48(7):1135-40. PubMed ID: 6225469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fibrinogen catabolism within the procoagulant VX-2 tumor of rabbit lung in vivo: Effluxing fibrin(ogen) fragments contain antiangiogenic activity.
    Hatton MW; Southward SM; Legault KJ; Ross BL; Clarke BJ; Bajzar L; Blajchman MA; Singh G; Richardson M
    J Lab Clin Med; 2004 Apr; 143(4):241-54. PubMed ID: 15085083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incorporation of fragment X into fibrin clots renders them more susceptible to lysis by plasmin.
    Schaefer AV; Leslie BA; Rischke JA; Stafford AR; Fredenburgh JC; Weitz JI
    Biochemistry; 2006 Apr; 45(13):4257-65. PubMed ID: 16566600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Screening for fibrin specific monoclonal antibodies: the development of a new procedure.
    Tymkewycz PM; Creighton-Kempsford LJ; Hockley D; Gaffney PJ
    Thromb Haemost; 1992 Jul; 68(1):48-53. PubMed ID: 1514172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Degradation pathway of fibrinogen by plasmin.
    Budzynski AZ; Marder VJ
    Thromb Haemost; 1977 Dec; 38(4):793-800. PubMed ID: 146273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fibrinogen St. Gallen I (gamma 292 Gly--> Val): evidence for structural alterations causing defective polymerization and fibrinogenolysis.
    Stucki B; Schmutz P; Schmid L; Haeberli A; Lämmle B; Furlan M
    Thromb Haemost; 1999 Feb; 81(2):268-74. PubMed ID: 10064005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Soluble fibrin species in arterial thrombi.
    Sandbaek G; Bjørnsen S; Sobel JH; Nieuwenhuizen W; Matsueda G; Brosstad F
    Blood Coagul Fibrinolysis; 2000 Jan; 11(1):1-5. PubMed ID: 10691094
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.